Literature DB >> 21338576

Protein tyrosine kinases in neutrophil activation and recruitment.

Alexander Zarbock1, Klaus Ley.   

Abstract

Migration of leukocytes into tissue is a key element of innate and adaptive immunity. The first contact of leukocytes with endothelial cells is mediated by engagement of selectins with their counter-receptors which results in leukocyte rolling. During rolling, leukocytes collect different inflammatory signals that activate intracellular signaling pathways. Integration of these signals induces leukocyte activation, firm arrest, post-adhesion strengthening, intravascular crawling, and transmigration. In neutrophils, like in T-cells and platelets, both G-protein-coupled receptor-dependent and -independent activation pathways exist that lead to integrin activation. Accumulating evidence suggests that different protein tyrosine kinases play key roles in signal transduction pathways regulating neutrophil activation and recruitment to inflammatory sites. This review focuses on the role of protein tyrosine kinases of the Src, Syk, and Tec families for neutrophil activation and recruitment.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21338576     DOI: 10.1016/j.abb.2011.02.009

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  13 in total

Review 1.  The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDL.

Authors:  Yury I Miller; Soo-Ho Choi; Philipp Wiesner; Yun Soo Bae
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Ezrin-radixin-moesin-binding sequence of PSGL-1 glycoprotein regulates leukocyte rolling on selectins and activation of extracellular signal-regulated kinases.

Authors:  Caroline Spertini; Bénédicte Baïsse; Olivier Spertini
Journal:  J Biol Chem       Date:  2012-02-06       Impact factor: 5.157

Review 3.  Neutrophil migration: moving from zebrafish models to human autoimmunity.

Authors:  Miriam A Shelef; Sebastien Tauzin; Anna Huttenlocher
Journal:  Immunol Rev       Date:  2013-11       Impact factor: 12.988

4.  The Neutrophil Btk Signalosome Regulates Integrin Activation during Sterile Inflammation.

Authors:  Stephanie Volmering; Helena Block; Mark Boras; Clifford A Lowell; Alexander Zarbock
Journal:  Immunity       Date:  2016-01-05       Impact factor: 31.745

5.  A sharp fluctuation in peripheral blood cells shortly after dasatinib administration.

Authors:  Jun Imagawa; Hideo Tanaka; Kana Matsumoto; Kunihiko Morita; Yuka Harada; Hironori Harada
Journal:  Int J Hematol       Date:  2012-07-15       Impact factor: 2.490

6.  Dasatinib inhibits proinflammatory functions of mature human neutrophils.

Authors:  Krisztina Futosi; Tamás Németh; Robert Pick; Tibor Vántus; Barbara Walzog; Attila Mócsai
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

7.  Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis.

Authors:  Fernanda Ferreira Cruz; Lucas Felipe Bastos Horta; Lígia de Albuquerque Maia; Miquéias Lopes-Pacheco; André Benedito da Silva; Marcelo Marco Morales; Cassiano Felippe Gonçalves-de-Albuquerque; Christina Maeda Takiya; Hugo Caire de Castro-Faria-Neto; Patricia Rieken Macedo Rocco
Journal:  PLoS One       Date:  2016-01-20       Impact factor: 3.240

8.  Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis.

Authors:  Priscila J Carneiro; Amanda L Clevelario; Gisele A Padilha; Johnatas D Silva; Jamil Z Kitoko; Priscilla C Olsen; Vera L Capelozzi; Patricia R M Rocco; Fernanda F Cruz
Journal:  Front Physiol       Date:  2017-03-15       Impact factor: 4.566

9.  PKC-dependent human monocyte adhesion requires AMPK and Syk activation.

Authors:  Mei-Ying Chang; Duen-Yi Huang; Feng-Ming Ho; Kuo-Chin Huang; Wan-Wan Lin
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

Review 10.  Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Authors:  Jose A Gomez-Puerta; Attila Mócsai
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.